Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. The data search targeted conventional (I, Y, Lu, Re, Re, Sm, Sr, Er) and emergent (Cu, Sc, Ra, Ho, Tb, Tb, Pb/Bi, Ac, Bi, At, Sn) RNs. Starting from this time frame, authors have analyzed and interpreted this scientific trend quantitatively first, and qualitatively after.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385165 | PMC |
| http://dx.doi.org/10.3390/molecules24030640 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [Tc]Tc-labeled counterparts be used to estimate dosimetry?
EJNMMI Radiopharm Chem
January 2025
Department of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
Background: Gastrin releasing peptide receptor (GRPR)-directed radiopharmaceuticals for targeted radionuclide therapy may be a very promising addition in prostate and breast cancer patient management. Aiming to provide a GRPR-targeting theranostic pair, we have utilized the Tc-99m/Re-188 radiometal pair, in combination with two bombesin based antagonists, maSSS-PEG2-RM26 and maSES-PEG2-RM26. The two main aims of the current study were (i) to elucidate the influence of the radiometal-exchange on the biodistribution profile of the two peptides and (ii) to evaluate the feasibility of using the [Tc]Tc labeled counterparts for the dosimetry estimation for the [Re]Re-labeled conjugates.
View Article and Find Full Text PDFEnhancing the radionuclide theranostic concept through the radiohybrid approach.
RSC Med Chem
November 2024
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research Bautzner Landstraße 400 D-01328 Dresden Germany
Radionuclide theranostics - a fast-growing emerging field in radiopharmaceutical sciences and nuclear medicine - offers a personalised and precised treatment approach by combining diagnosis with specific and selective targeted endoradiotherapy. This concept is based on the application of the same molecule, labelled with radionuclides possessing complementary imaging and therapeutic properties, respectively. In radionuclide theranostics, radionuclide pairs consisting of the same element, such as Cu/Cu, Pb/Pb or I/I are of significant interest due to their identical chemical and pharmacological characteristics.
View Article and Find Full Text PDFEmerging role of electrochemistry in radiochemical separation of medically important radiometals: state of the art.
Am J Nucl Med Mol Imaging
October 2024
Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay, Mumbai 400085, India.
Electrochemical separation technology has brought a renaissance in the field of nuclear medicine towards obtaining clinical-grade radiometals for preparation of a wide variety of radiopharmaceuticals. This article is a comprehensive summary of the electrochemical processes developed for the separation of radiometals that could be used for diagnostic or therapeutic applications in nuclear medicine. For using electrochemistry as a tool for the separation of radiometals, intricate knowledge is essential to understand the basic parameters of electrochemical separation processes which include applied potential, selection of electrolyte, choice of the electrode, the temperature of the electrolyte, pH of the electrolyte and time of electrolysis.
View Article and Find Full Text PDFTowards Optimal Automated Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate.
J Labelled Comp Radiopharm
December 2024
Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, Montpellier, France.
DOTA-functionalized bisphosphonates can be useful tools for PET imaging of bone metastases when radiolabeled with Ga. Moreover, the versatility of DOTA allows the complexation of radiometals with therapeutic applications (e.g.
View Article and Find Full Text PDFA Brief Review of Radiolabelling Nucleic Acid-Based Molecules for Tracking and Monitoring.
J Labelled Comp Radiopharm
November 2024
Department of Life Sciences, University of Bath, Bath, UK.
The rise of nucleic acid-based therapeutics continues apace. At the same time, the need for radiolabelled oligonucleotides for determination of spatial distribution is increasing. Complex molecular structures with mostly multiple charges and low solubility in organic solvents increase the challenge of integrating radionuclides.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!